Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

For the first time, UAB researchers have cured mice with diabetes type 1

10.05.2002


A team of researchers from the Universitat Autònoma de Barcelona (UAB) has cured mice with diabetes type 1 for the first time. In the experiment, the diabetic mice completely recovered from the disease after having suffered excesses of glucose in their blood. Although the mice used were transgenic, the researchers are sure that there will soon be a genic therapy based on this discovery that will cure non-transgenic mice with diabetes type 1, and which, within a few years, will also be able to cure people. The study was published in last edition of Journal of Clinical Investigation.



A research team led by Fatima Bosch, professor in the Department of Biochemistry and Molecular Biology at the UAB, has studied the effects of protein IGF-I on mice with diabetes type 1, i.e. the type of diabetes produced by a decrease in the number of beta cells in the pancreas, the ones which produce insulin. In order to study this effect, the researchers used mice that were genetically modified so that the beta cells in their pancreases would produce protein IGF-I, and have compared the development of diabetes type 1 in this type of mice to the evolution of the disease in control mice (without genetic modifications).

The results of the experiments clearly show that in the transgenic mice with the gene that codifies for protein IGF-I activated in beta cells, the induction of experimental diabetes leads to the replication of these cells, their programmed cellular death is counteracted (apoptosis) and the resident mother cells in the conducts of the pancreas are induced to develop insulin-producing beta cells. All these effects lead to the mice completely recovering from the disease, re-establishing absolutely normal levels of glucose in their blood.


The team of UAB scientists chose to experiment with this protein because it has provided excellent results in vitro – it causes the replication of beta cells and counteracts apoptosis – and moreover, mice in which there is destruction of the gene that codifies the IGF-I receptor have very small pancreatic islets (the conglomerates of the beta cells in the pancreas).

This is the first time in which it has been demonstrated that a curative therapy for diabetes is possible, and could imply important advantages over other therapies that are currently being investigated, such as the transplant of islets or beta cells cultivated in vitro. Moreover, in the therapy developed by Doctor Fatima Bosch’s team, the effect of IGF-I does not occur until the animal suffers the destruction of its beta cells. Therefore, non-diabetic transgenic animals are perfectly normal, without any alterations or secondary effects.

The researchers are sure that the next stage of the research programme, the curing of normal (i.e. non-transgenic) mice with diabetes 1 by mean of genic therapy, will probably take place in the near future. Once the scientists have successfully carried out tests with experimental animals, they will be able to consider applying the technique to humans, although this will not be for some time. In order to cure diabetes type 1, viral vectors (innocuous viruses) carrying the gene that codifies for IGF-I will have to be injected into the pancreas.

The research, published in last edition of Journal of Clinical Investigation, has involved the participation of researchers from the Department of Biochemistry and Molecular Biology at the UAB, specifically the Unit from this department based in the Faculty of Veterinary Science, along with members of the Centre for Animal Biotechnology and Genetic Therapy (CBATEG) at the Biocampus research complex of the Universitat Autònoma de Barcelona. The research was financed by the Fondo de Investigación Sanitaria (Health Research Fund), the Plan Nacional de I+D (National R&D Plan) of the Spanish Ministry for Education and Culture, the TV3 Marató Foundation, the Generalitat de Catalunya’s General Research Management and the European Community Training and Mobility Program.

Octavi López Coronado | alphagalileo
Further information:
http://www.uab.es

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>